Multi-Assay Evaluation Demonstrates Moderate Anticancer Activity of Hesperidin
Journal of Integrative and Translational Biomedicine · 2026
DOI: 10.67316/jintb.v1.i3.54 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Integrative and Translational Biomedicine, 2026. Verfasst von Omkar Shrikant Upase. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cancer remains a major global health challenge, and despite therapeutic advances, limitations related to toxicity and resistance underscore the need to explore safer bioactive compounds. Hesperidin has been reported to exhibit multiple biological activities, but its anticancer potential across functional and metabolic endpoints remains insufficiently characterized. Therefore, the present study aimed to evaluate the cytotoxic and anticancer potential of hesperidin using a multi-tiered experimental approach, which includes toxicity screening, in vitro cytotoxicity, cell migration analysis, and metabolic assessment.
Methods
Cytotoxicity was initially assessed using the brine shrimp lethality assay following cancer cell lines A549, HT29, and HEPG2. The effect on cell migration was analyzed using a scratch assay. In addition, glucose uptake assays were conducted to assess the effect of hesperidin on Warburg phenotype. Standard drugs/compounds paclitaxel, 5-fluorouracil, curcumin, and CuSO₄ were used as references as applicable.
Results
Hesperidin exhibited dose-dependent cytotoxicity in brine shrimp lethality assay with moderate potency. In cancer cell lines, it showed measurable cytotoxic effects compared to standard chemotherapeutic agents. It inhibited cell migration in a concentration-dependent manner and partially reduced glucose uptake in HT29 cells. Hesperidin showed consistent multiple biological activities, affecting cell viability, migration, and metabolic function, but with moderate potency.
Conclusion
Results suggest that hesperidin is better suited as a lead scaffold or adjunct therapeutic candidate rather than a standalone anticancer agent.
Zitieren
APA
Upase, O. S. (2026). Multi-Assay Evaluation Demonstrates Moderate Anticancer Activity of Hesperidin. Journal of Integrative and Translational Biomedicine. https://doi.org/10.67316/jintb.v1.i3.54
Vancouver
Upase OS. Multi-Assay Evaluation Demonstrates Moderate Anticancer Activity of Hesperidin. Journal of Integrative and Translational Biomedicine. 2026. doi:10.67316/jintb.v1.i3.54
BibTeX
@article{Upase2026,
author = {Upase, Omkar Shrikant},
title = {Multi-Assay Evaluation Demonstrates Moderate Anticancer Activity of Hesperidin},
journal = {Journal of Integrative and Translational Biomedicine},
year = {2026},
doi = {10.67316/jintb.v1.i3.54}
}
EUVIMED